Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KP 673

Next Previous
Drug Profile

KP 673

Alternative Names: KP673

Latest Information Update: 28 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SciClone Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in China (PO, Tablet)
  • 22 Apr 2020 NMPA approves IND application for KP 673 in Non-small cell lung cancer (SciClone Pharmaceuticals pipeline, April 2020)
  • 22 Apr 2020 SciClone Pharmaceuticals plans a clinical trial for Non-small cell lung cancer (PO) (SciClone Pharmaceuticals pipeline, April 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top